We analyzed Brazil's efforts in reducing child mortality, improving maternal and child health, and reducing socioeconomic and regional inequalities from 1990 through 2007. We compiled and reanalyzed data from several sources, including vital statistics and population-based surveys. We also explored the roles of broad socioeconomic and demographic changes and the introduction of health sector and other reform measures in explaining the improvements observed. Our findings provide compelling evidence that proactive measures to reduce health disparities accompanied by socioeconomic progress can result in measurable improvements in the health of children and mothers in a relatively short interval. Our analysis of Brazil's successes and remaining challenges to reach and surpass Millennium Development Goals 4 and 5 can provide important lessons for other low- and middle-income countries.
Resumo: O Programa Nacional de Imunizações (PNI), coordenado pelo Ministério da Saúde, de forma compartilhada com as secretarias estaduais e municipais de saúde, vem se consolidando como uma das principais e mais relevantes intervenções em saúde pública, com a conquista de resultados importantes, como a certificação de área livre da circulação do poliovírus selvagem, a eliminação da circulação do vírus da rubéola e pelo importante impacto na redução dos casos e mortes pelas doenças imunopreveníveis, a partir da sua criação em 1973. O Brasil é um dos países que oferece o maior número de vacinas, de forma gratuita, com 15 vacinas para crianças, 9 para os adolescentes, cinco para os adultos e idosos. A partir dessa expansão do programa e da manutenção de elevadas coberturas vacinais, foi possível observar o rápido impacto na diminuição das doenças imunopreveníveis, mudando completamente o cenário epidemiológico dessas doenças no país, ao longo destas últimas quatro décadas. Atualmente, o país vive um contexto em que aumenta a parcela da população sem vacinação adequada. Na medida em que as doenças passam a não circular mais, justamente porque se mantiveram elevadas coberturas vacinais principalmente a partir dos anos 2000, muitas doenças tornaram-se desconhecidas, fazendo com que algumas pessoas não tenham noção do perigo representado por elas. É necessário, portanto, entender os múltiplos fatores que estão contribuindo para essa diminuição, criando, dessa forma, o risco de ressurgimento de doenças graves já controladas ou eliminadas na população.
This study aimed to estimate the prevalence of genital, anal and oral HPV infection in Brazil through systematic review and meta-analysis. Methods We searched EMBASE, LILACS, MEDLINE, Web of Science and SciELO from inception to December 2018. Original research articles that assessed the prevalence of genital (i.e., cervical, penile), anal and oral HPV infection in Brazil were selected in pairs by independent authors. No sex, age, HPV vaccination, language or date restrictions were applied. HPV prevalence was estimated and stratified according to risk factors population and by geographic area throughout the country. The study prevalence was pooled using a random effects model. Analysis was performed using R (version 3.5.2), packages meta version 4.9-4 and metaphor 2.0-0. This review is registered on PROSPERO under protocol number CRD42016032751. Results We identified 3,351 references. After the screening process, 139 of them were eligible for this systematic review (57,513 total participants). Prevalence of cervical HPV was 25.41% (95% CI 22.71-28.32). Additionally, prevalence was 36.21% (95% CI 23.40, 51.33) in the penile region, 25.68% (95%CI 14.64, 41.04) in the anal region, and 11.89% (95%CI 6.26, 21.43) in the oral region. Subgroup analysis showed prevalence in each anatomic site was higher in high-risk populations. Conclusion The prevalence of HPV is high in the Brazilian population and varies by population risk and anatomic body site, with lower rates in the oral cavity compared to that in the cervical, penile
BackgroundIn addition to screening by Pap smears, vaccination against human papillomavirus (HPV) can dramatically reduce cervical cancers caused by the virus. The acceptance of HPV vaccination is directly related to HPV knowledge. This research aimed to evaluate knowledge about HPV and vaccination among men and women aged 16–25 years who use the public health system in Brazil.MethodsThis was a cross-sectional, multicenter study of sexually active young adults recruited from 119 primary care units between 2016 and 2017. All participants answered a face-to-face standardized questionnaire.ResultsOf 8581 participants, the mean percentage of correct answers about HPV and vaccination was 51.79% (95% CI 50.90-52.67), but 75.91% (95% CI 74.13-77.69) had awareness of the HPV vaccination. Women answered a higher proportion of questions correctly than men did (p = 0.0003). Lower education level was the variable that most interfered with knowledge. The best information sources for knowledge were both health professionals and the media (1.33%, 95% CI 1.03-1.70).ConclusionsThe results emphasize the importance of educational programs about HPV and vaccination among young adults, especially in socially disadvantaged populations. These findings can help to increase the vaccination rate in the country and to stimulate public health policies.
IntroductionHuman papillomavirus (HPV) is associated with the development of genital warts and different types of cancer, including virtually all cervical cancers and a considerable number of penile, anal and oropharyngeal cancers. Data regarding the prevalence of HPV infection in Brazil are limited and fragmented. We aim to determine HPV prevalence in sexually active women and men aged 16–25 years and to investigate regional differences in virus prevalence and types.Methods and analysisThis is a nationwide, multicentric, cross-sectional, prospective study that will include participants aged 16–25 years from all Brazilian capital cities. Recruitment will occur in primary health units by trained health professionals who will be responsible for collecting biological samples and interviewing the volunteers. After signing informed consent, all participants will answer a questionnaire that will collect sociodemographic and behavioural data. All samples will be processed in a certified central laboratory, and strict quality control will be performed by many different procedures, including double data entry, training and certification of primary care health professionals responsible for data collection, simulation of interviews, and auditing and monitoring of visits. The sample size will be standardised based on the population distribution of each capital using SAS and R statistical software.Ethics and disseminationThe project was approved by the research ethics committee of the main institution and the corresponding ethics committees of the recruitment sites. This will be the first Brazilian nationwide study to determine overall HPV prevalence and to examine regional differences and social, demographic and behavioural factors related to HPV infection. Critical analysis of the study results will contribute to epidemiological knowledge and will set a baseline for future evaluation of the impact of the National HPV Vaccination Program.
1Este é um artigo de acesso aberto distribuído sob os termos da Licença Creative Commons Attribution-NonCommercial-NoDerivs 3.0 IGO, que permite o uso, distribuição e reprodução em qualquer meio, desde que o trabalho original seja devidamente citado. Não são permitidas modificações ou uso comercial dos artigos. Em qualquer reprodução do artigo, não deve haver nenhuma sugestão de que a OPAS ou o artigo avaliem qualquer organização ou produtos específicos. Não é permitido o uso do logotipo da OPAS. Este aviso deve ser preservado juntamente com o URL original do artigo. Os eventos adversos pós-vacinação (EAPV) são ocorrências clínicas indesejadas ou não intencionais que ocorrem após a vacinação, sem que haja necessariamente uma relação causal com o uso da vacina ou outro imunobiológico (1). Eventos desse tipo podem envolver um sintoma, uma doença ou um achado laboratorial anormal. Podem também ser relacionados à composição da vacina, à técnica usada em sua administração, aos próprios indivíduos vacinados -sendo a predisposição genética individual um importante fator no desenvolvimento de algumas desordens após a vacinação -, ou à coincidência com outros agravos (1-4). Análise do Sistema deOs EAPV não graves são mais frequentes e causam manifestações clínicas de leves a moderadas no local ou próximo ao sítio de administração da vacina (5-7). RESUMO Objetivo. Descrever as características das notificações de eventos adversos pós-vacinação (EAPV) no Sistema de Informação da Vigilância de EAPV (SI-EAPV) on-line nos primeiros 2 anos de operação do sistema. Método. Foi realizado um estudo descritivo dos registros de EAPV notificados no SI-EAPV Palavras-chaveVacinação; sistemas de informação; epidemiologia descritiva; saúde pública; Brasil.
Objective: to calculate mortality rates on the first day of life from 2010 to 2015 in eight Brazilian Federative Units providing better quality information, to assess associated factors and to classify deaths by underlying causes and avoidability. Methods: this was a descriptive study; mortality rates were compared according to maternal and child characteristics; avoidability analysis used the 'Brazilian list of avoidable causes of death'. Results: 21.6% (n=20,791) of all infant deaths occurred on the first day of life; the mortality rate reduced from 2.7 to 2.3 deaths/1,000 live births; rates were higher in live births with low birthweight and preterm births, and among babies born to mothers with no schooling; main causes of death were respiratory distress syndrome (8.9%) and extreme immaturity (5.2%); 66.3% of causes of death were avoidable. Conclusion: 2/3 of deaths on the first day of life could have been avoided with adequate care for women during pregnancy and delivery and adequate care for live births.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.